Lantern Pharma to Participate in Two Upcoming Virtual Investor Conferences During September

Rhea-AI Summary

Lantern Pharma (NASDAQ: LTRN) announced participation in two virtual investor conferences in September 2021. Panna Sharma, President & CEO, will host one-on-one meetings at the Colliers Institutional Investor Conference on September 9-10. Additionally, he will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, with a presentation available on-demand starting September 13 at 7:00 AM ET. Lantern Pharma leverages its RADR® A.I. platform to discover targeted therapies for oncology, complimented by four drug candidates in development.

DALLAS, Sept. 7, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR^® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced it will be participating in two upcoming virtual investor conferences.

Colliers Institutional Investor Conference
Panna Sharma, President & CEO of Lantern Pharma, will be hosting one-on-one meetings at the 2021 Colliers Institutional investor conference being held virtually September 9-10, 2021. Investors interested in arranging a meeting should contact their Collier sales representative.

H.C. Wainwright 23^rd Annual Global Investment Conference
Mr. Sharma will be presenting at the H.C. Wainwright 23^rd Annual Global Investment Conference being held virtually between September 13-15, 2021. Lantern's presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 13, 2021, at 7:00 AM Eastern Time. The webcast can be accessed here and on the investor relations section of Lantern's website at https://ir.lanternpharma.com/. Management will also be participating in one-on-one meetings with qualified members of the investor community throughout the conference.

About Lantern Pharma
Lantern Pharma (LTRN) is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR^® A.I. platform and machine learning to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically targeted therapeutics. Lantern is currently developing four drug candidates and an ADC program across eight disclosed tumor targets, including two phase 2 programs. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, Lantern's approach represents the potential to deliver best-in-class outcomes. More information is available at: www.lanternpharma.com and Twitter @lanternpharma.

CONTACTS:

Investor Relations
David Waldman, Crescendo Communications, LLC
IR@lanternpharma.com
212-671-1021

Public Relations
Nicholas Koulermos, Vice President – 5W Public Relations
lantern@5wpr.com
646-843-1812

View original content to download multimedia:https://www.prnewswire.com/news-releases/lantern-pharma-to-participate-in-two-upcoming-virtual-investor-conferences-during-september-301370269.html

SOURCE Lantern Pharma

FAQ

What is Lantern Pharma's participation in upcoming investor conferences?

Lantern Pharma will participate in the Colliers Institutional Investor Conference on September 9-10 and the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021.

Who will represent Lantern Pharma at the investor conferences?

Panna Sharma, the President & CEO of Lantern Pharma, will represent the company at both conferences.

When will Lantern Pharma's presentation be available for the H.C. Wainwright Conference?

Lantern Pharma's presentation will be available on-demand starting September 13, 2021, at 7:00 AM Eastern Time.

What focus areas does Lantern Pharma's RADR® A.I. platform target?

The RADR® A.I. platform is focused on discovering biomarkers to identify patients who are most likely to benefit from Lantern Pharma's targeted therapies.

What drug development programs is Lantern Pharma pursuing?

Lantern Pharma is developing four drug candidates and an Antibody-Drug Conjugate (ADC) program across eight tumor targets, including two phase 2 programs.